TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of ADHD (any sub-type) with oppositional defiant disorder.~* Clinical diagnosis of ADHD (any sub-type) with conduct disorder.~* Clinical diagnosis of other specified ADHD with oppositional defiant disorder.~* Clinical diagnosis of other specified ADHD with conduct disorder.~* Clinical diagnosis of unspecified ADHD with oppositional defiant disorder.~* Clinical diagnosis of unspecified ADHD with conduct disorder.~Exclusion Criteria:~* Participant who do not qualify for inclusion criteria.~* Participant who are not willing to join the study.~* Epilepsy.~* Neuro-genetic syndromes.~* Brain tumors.~* Autism.~* Participants who are under psychiatric medication and have changed it (dose or kind) in the last month.~* Congenital heart, kidney of liver defects.~* Cardiomyopathies.~* Past hypersensitivity to Methylphenidate or Risperidone.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate (Type: ACTIVE_COMPARATOR): Participants in this arm will be given either Concerta - a long acting (12 hours) Methylphenidate pill - once daily, in the morning (starting dose 1 mg/kg, max dose 2 mg/kg), or Ritalin LA - a long acting (10 hours) Methylphenidate pill - once daily, in the morning (starting dose 0.6 mg/kg, max dose 1.5 mg/kg) for children who can not swallow pills.
- Risperidone (Type: ACTIVE_COMPARATOR): Participants in this arm will be given a low dose of Risperidone. Starting dose will be 0.5 mg/d, max dose will be 2 mg/d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of a Self-fixating Mesh in Unilateral Open Inguinal Hernia Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing primary unilateral open Inguinal Hernia Repair .~* patients undergoing elective surgery.~* above the age of 18 years old~Exclusion Criteria:~* patients having repeated Inguinal Hernia.~* patients having bilateral Hernia.~* patients undergoing laparoscopic surgery.~* patients undergoing non-elective surgery.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Self-fixating Mesh (Type: None): patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional Sucrase Deficiency in Short Bowel Syndrome Patients with Intestinal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Short bowel syndrome, of all ages, with dependence on parental support to provide at least 50% of fluid or caloric needs.~* Must be on diet containing sucrose.~* Must be willing and able to sign informed consent~* Adult and Pediatric patients (all ages)~Exclusion Criteria:~* Current IV antibiotic administration for confirmed bout of bacteremia.~* No enteral nutrition~* Any condition, disease, illness, or circumstance that in the investigator's opinion puts the subject at any undue risk, prevents completion of the study, or interferes with analysis of the study results

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sucrase intervention followed by placebo (Type: EXPERIMENTAL): Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.
- Placebo followed by sucrase intervention (Type: EXPERIMENTAL): Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FDDA Utilization Study (FDDAU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Physicians:~* Established physicians with specialization in general internal medicine (GP).~* Regular consultation of patients with a complaint of a not yet explained fatigue (between 1 every 2 weeks and 5 per week)~Patients:~* 18 to 80 years old~* Male or female~* Fatigue of not yet explained origin~* The reason for encounter had to be fatigue (as a main symptom) of not yet explained origin, which had lasted for at least 2 weeks, but no longer than 2 years before inclusion.~* Subject (or legally acceptable representative) had provided the appropriate written informed consent. Subject had to provide written informed consent before any study-specific procedures were performed.~Exclusion Criteria:~Physicians:~* Works in/or is related to an iron center (a medical center known to be primarily inclined to prescribing intravenous iron supplements in cases of fatigue)~* Known as being experienced in fatigue or CFS (more than five patients per week) Specialized in psychosomatic medicine (in Switzerland: Fähigkeitsausweis SAPPM / Attestation ASMPP)~* Physicians having a sub-specialty (other than internists working as GPs in a private practice)~* Participation in the feasibility evaluation (excl. for utilization study)~Patients:~* Subject had known pre-existing anemia~* Subject with previous treatment of fatigue by a medical doctor during the last 3 months~* Subject had any pre-known disease, which is responsible for patient's fatigue with a high probability, according to GP's judgement (e.g., CHF, CKD, IBD, RA, MS, Cancer, etc...).~* Subject was known to take any drugs, which could be responsible for inducing fatigue symptoms, according to GP's judgement (e.g., antihistamines, antidepressants, benzodiazepines, hypnotics, anxiolytics, opioid formulations, etc...).~* Subject had a history of drug or alcohol abuse within 2 years prior to the 1st study visit (V1).~* Subject was currently enrolled or had completed any other clinical trial \< 30 days prior to 1st study visit (V1).~* Subject had previously participated in the The Fatigue Differential Diagnosis Aid (FDDA) for General Practitioners: Feasibility study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FDDA Group (Type: ACTIVE_COMPARATOR): Fatigue anamnesis was done with the help of the Fatigue Differential Diagnosis Aid.
- Non-FDDA group (Type: NO_INTERVENTION): Fatigue anamnesis was done without the help of the Fatigue Differential Diagnosis Aid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with remitting or progressive multiple sclerosis defined by McDonald criteria revised in 2005, with an EDSS between 6 and 7,5~* Aged between 18 and 65 years~* Patients able to maintain the Powerbreathe~* Not to have had a flare-up since at least 6 weeks~* Patients at least 4 weeks since a corticoid bolus~* Patients at least 6 weeks since a botulinum toxin injection~* Patients at least 4 weeks since a pulmonary infection~* Questionnaire EMIF-SEP \>= 55~* Patients given their informed consent~* Patients who benefit or are affiliated to a social security regimen~Exclusion Criteria:~* Patients with neurologic antecedents other that multiple sclerosis~* Patients with respiratory disorders other than those induced by multiple sclerosis~* Patients with orthopedic, cardiac, and rheumatologic invalidating antecedents~* Patients with comprehension or cognitive disorders impeding the realization of rehabilitation~* Pregnant women~* Patients under legal guardianship, or safeguard of justice~* Patients participating or planning participate within the 3 months of the study to another clinical research project

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Respiratory rehabilitation (Type: EXPERIMENTAL): Respiratory rehabilitation: Powerbreathe training of the inspiratory muscles at home twice a day (2 sessions of 30 inspirations / day) during 10 weeks
- control group (Type: NO_INTERVENTION): No respiratory rehabilitation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed CLL diagnosis and active CLL requiring treatment~* considered inappropriate for fludarabine-based therapy~* not been treated for CLL before~* fully active at a minimum or fully capable of selfcare and up and about more than 50% of waking hours~* age 18yrs or older~* signed written informed consent~Exclusion Criteria:~* prior CLL therapy~* abnormal/inadequate blood values, liver, and kidney function~* certain heart problems, active or chronic infections, serious significant diseases, active autoimmune hemolytic anemia (AIHA) requiring treatment, other current cancer or within last 5 years~* CLL transformation~* CLL central nervous system involvement~* current participation in other clinical study~* inability to comply with the protocol activities~* lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ofatumumab + chlorambucil (Type: EXPERIMENTAL): ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
- chlorambucil (Type: ACTIVE_COMPARATOR): chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A RCT on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing FET Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing FET treatment cycles~* Normal uterine cavity as shown on transvaginal scanning or saline sonogram done at baseline~* endometrial thickness \>=8mm during the stimulated IVF cycle and FET cycle~Exclusion Criteria:~* Pregnancy in previous IVF or FET cycles~* Presence of hydrosalpinx not surgically corrected prior to FET~* Presence of endometrial polyp or fibroid distorting uterine cavity~* IVF cycles carried out for preimplantation genetic diagnosis~* Arrange for blastocyst transfer~* Use of donor oocytes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- EA (Type: EXPERIMENTAL): in the cycle immediately preceding the scheduled FET treatment, an endometrial biopsy would be arranged on day 21-23 of the menstrual cycles and they will be instructed to use non-hormonal means of contraception during that cycle.
- Control (Type: PLACEBO_COMPARATOR): The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix but not into the uterine cavity, only entering the endocervical canal as control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Peroral Myotomy for Treatment of Achalasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with symptomatic achalasia and pre-op barium swallow, manometry and esophagogastroduodenoscopy which are consistent with the diagnosis~* persons of age \> 18 years with medical indication for surgical myotomy or Endoscopic balloon dilatation~* Signed written informed consent.~Exclusion Criteria:~* Patients with previous surgery of the stomach or esophagus~* Patients with known coagulopathy~* Previous achalasia-treatment with surgery~* Patients with liver cirrhosis and/or esophageal varices~* Active esophagitis~* Eosinophilic esophagitis~* Barrett's esophagus~* Pregnancy~* Stricture of the esophagus~* Malignant or premalignant esophageal lesion~* Candida esophagitis~* Hiatal hernia \> 2cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peroral endoscopic myotomy (Type: EXPERIMENTAL): Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has signed and dated an Informed Consent Form.~2. Subject is classified as a ASA (American Society of Anesthesiologists) status I-III~3. Subject is age 18- 75 years old.~4. Subject is having primary total hip arthroplasty~5. No contraindication to peripheral nerve catheter ( local infection or hypocoagulable state)~6. Patient willing to receive spinal anesthesia as operative anesthesia~7. No known drug allergies to study medications~8. Patients not expected to receive therapeutic anticoagulation in the postoperative period.~Exclusion Criteria:~1. Subject inability to provide adequate informed consent.~2. Age younger than 18 years or older than 75 years~3. Any contraindication to the placement of lumbar plexus catheter, including local infection, hypocoagulable state.~4. ASA (American Society of Anesthesiologists) physical status of IV or greater~5. Any chronic painful conditions~6. Preoperative opioid use~7. Coagulation abnormalities or patients who are expected to be on therapeutic anticoagulants postoperatively

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Lumbar Plexus Block with Parasacral Nerve Block (Type: EXPERIMENTAL): Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
- Lumbar Plexus Nerve Block (Type: ACTIVE_COMPARATOR): Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~No sham/placebo parasacral (sciatic) blocks will be performed in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rome III Criteria for IBS:~Patients must have recurrent abdominal pain or discomfort at least 3 days per month during the previous 3 months that is associated with 2 or more of the following:~* Relieved by defecation~* Onset associated with a change in stool frequency~* Onset associated with a change in stool form or appearance~In addition, patients have to experience at least two of the following symptoms for at least 25% of the time \[11\]:~* Altered stool frequency (\< 3 bowel movements per week)~* Altered stool form (lumpy/hard i.e. Bristol type I-III \[see appendix 1\])~* Altered stool passage (straining, urgency, or a feeling of incomplete evacuation)~* Passage of mucus, bloating, or a feeling of abdominal distension~Exclusion Criteria:~* Previous allergy to mosapride~* Nocturnal Symptoms (pain in the middle of the night, or other nocturnal symptoms which suggest an organic disease)~* Age \< 18 years~* History of bloody stools or melena~* Diarrhea (\>3 bowel movements per day)~* Constitutional symptoms (fever, weight loss)~* Severe constipation (\< 1 bm/week)~* Pregnancy or lactation~* Patients with history of cardiac arrhythmias~* QT prolongation on baseline ECG~* Chronic laxative use and dependence~* Patients with previous history of congenital heart disease~* Patients with previous history of hypokalemia or hyperkalemia~* Patients taking the following classes of drugs: HIV antivirals, macrolides, anti-arrhythmics, and azole drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Mosapride
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sonographic Features of Cellulitis and Failure of Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older Symptoms of cellulitis (localized warmth, erythema, swelling or tenderness)~Exclusion Criteria:~Admitted for inpatient antibiotics Unable to consent Septic appearing crepitus on exam animal bite soft tissue abscess osteomylitis cellulitis requiring surgical debridement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with Cellulitis (Type: None): Patients with uncomplicated cellulitis treated as outpatients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues